BPC-157 vs TB-500: evidence, safety and FDA status
PepsRadar · Comparison · AI-assisted, written from the checked facts on each profile · Content updated (how dates work) · Not reviewed by a medical professional
The short answer
Neither is FDA-approved, and neither has a controlled human trial. BPC-157’s human record is a two-person safety pilot and a small knee-pain chart review with no control group. TB-500 has no human study in our sources, and FDA found no human exposure data; much of the biology quoted for it comes from the full thymosin beta-4 protein, not the fragment sold as TB-500.
Key differences
Different molecules: BPC-157 is a 15-amino-acid peptide; TB-500 is usually described as a short fragment of thymosin beta-4, and sellers often do not state the exact sequence.
Human data: BPC-157 has two small uncontrolled reports; for TB-500, FDA found no human exposure data.
FDA flagged both for possible immune reactions and impurity problems in compounded products.
They are often sold together as a blend. Combining two compounds without human evidence adds a second unknown; it does not add up to a proven effect.
BPC-157 is a 15-amino-acid research peptide. Selected animal injury studies and a two-person human safety pilot explore different questions; neither establishes treatment benefit for injured patients.
TB-500 is associated with a short thymosin beta-4 fragment. Much of the biology cited in marketing instead concerns the full-length parent peptide.
Human evidence
No randomized trials · Retrospective chart review · Uncontrolled pilot
No human studies in our sources; animal and lab studies only
Human safety data
Very limited. BPC-157 is unapproved. Human safety data are limited to a two-person pilot and a small chart review, and FDA says it lacks the information to know whether it causes harm in people.
None. Unapproved fragment of thymosin beta-4. FDA found no human exposure data and flagged immune-reaction and impurity risks; its safety in people is unknown.
Boxed warning
No FDA label to carry one
No FDA label to carry one
Serious risks
FDA: possible immune reactions (immunogenicity) and peptide-impurity problems with compounded products
Product identity and purity of research-market products are unverified
Possible immune reactions (immunogenicity) and peptide impurities, per FDA's compounding safety listing
Conditions flagged
None flagged, because there is too little human safety data to assess
Unproven: BPC-157 heals tendons and ligaments in people.
False: TB-500 is the same thing as thymosin beta-4 and works the same way.
Each row comes from the BPC-157 and TB-500 profiles, where every fact links to its source. “Conditions flagged” lists the health conditions each profile’s Risks & interactions section mentions.
The human studies
BPC-157
BPC-157 · knee-pain chart review (2021)
Retrospective human chart review · 16 patients at one U.S. primary-care hormone clinic, reached by phone 6–12 months after a knee injection; 12 received BPC-157 alone and 4 received BPC-157 with thymosin beta-4.
The authors reported that 14 of 16 patients (87.5%) described significant knee-pain relief, including 11 of 12 who received BPC-157 alone.
Limitation: The knee problems varied, follow-up was inconsistent, and no imaging or function measures were used. The study did not systematically record side effects, so it says little about safety. Controlled trials would be needed to support a benefit.
Uncontrolled human pilot · Two adults aged 58 and 68 who had both received intravenous BPC-157 before the study.
No reported side effects or measurable changes in the tested organ-function biomarkers were observed during the short monitoring period.
Limitation: The study cannot detect uncommon or delayed harms, establish injury-healing efficacy, or validate research-use products. The authors’ broad safety conclusion exceeds what this design can establish. Larger controlled studies and pharmaceutical-quality identity checks remain necessary.
No human studies in our sources. See the TB-500 profile for the animal and lab research.
Results from different trials are not a head-to-head comparison: the people, preparations, durations and measures differ.
Bottom line
For injury recovery, the honest summary is the same for both: animal studies and mechanism research, not proof in people. The claim checks below cover the healing claims in detail.
PepsRadar does not give doses or usage instructions, and this page is not medical advice. For a prescription medicine, talk to your prescriber or pharmacist.
Plain-English summaries of new peptide studies, regulatory news and notable price changes from the sellers we track. No dosing advice. Unsubscribe anytime.
Peps